within Pharmacolibrary.Drugs.ATC.S;

model S01BC05
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 5.833333333333333e-06,
    adminDuration  = 600,
    adminMass      = 30 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.013,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0067,
    k12             = 4.6,
    k21             = 4.6
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>S01BC05</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) used for short-term management of moderate to severe pain, commonly following surgeries. It works by inhibiting cyclooxygenase (COX) enzymes, reducing the synthesis of prostaglandins. Ketorolac is approved for use in many countries and is available in oral, intravenous, intramuscular, and ophthalmic formulations. The ATC code S01BC05 refers specifically to its ophthalmic (eye drop) formulation for the treatment of eye pain and inflammation.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects, intravenous administration.</p><h4>References</h4><ol><li><p>Villa, R, et al., &amp; Cagnardi, P (2015). Pharmacokinetics of intravenous ketorolac in cats undergoing gonadectomy. <i>New Zealand veterinary journal</i> 63(3) 162–166. DOI:<a href=&quot;https://doi.org/10.1080/00480169.2014.987329&quot;>10.1080/00480169.2014.987329</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25523103/&quot;>https://pubmed.ncbi.nlm.nih.gov/25523103</a></p></li><li><p>Mroszczak, EJ, et al., &amp; Massey, I (1990). Ketorolac tromethamine pharmacokinetics and metabolism after intravenous, intramuscular, and oral administration in humans and animals. <i>Pharmacotherapy</i> 10(6 ( Pt 2)) 33S–39S. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2082311/&quot;>https://pubmed.ncbi.nlm.nih.gov/2082311</a></p></li><li><p>McLay, JS, et al., &amp; Anderson, BJ (2018). The pharmacokinetics of intravenous ketorolac in children aged 2 months to 16 years: A population analysis. <i>Paediatric anaesthesia</i> 28(2) 80–86. DOI:<a href=&quot;https://doi.org/10.1111/pan.13302&quot;>10.1111/pan.13302</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29266539/&quot;>https://pubmed.ncbi.nlm.nih.gov/29266539</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end S01BC05;
